U.S. Markets closed

Athersys, Inc. (ATHX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.5500-0.0800 (-4.91%)
At close: 4:00PM EDT
1.5500 0.00 (0.00%)
After hours: 06:37PM EDT

Athersys, Inc.

3201 Carnegie Avenue
Cleveland, OH 44115-2634
United States
216 431 9900

Full Time Employees97

Key Executives

NameTitlePayExercisedYear Born
Mr. William B. J. Lehmann Jr., M.B.A., J.D., MBAPres, COO, Sec. & Interim CEO533.6kN/A1966
Dr. John J. HarringtonCo-Founder, Chief Scientific Officer, Exec. VP & Director534.86kN/A1967
Mr. Ivor Macleod CPA, M.B.A.Chief Financial Officer & Principal Accounting Officer587.21kN/A1962
Ms. Laura K. Campbell CPA, CPASr. VP of Fin.371.36kN/A1964
Ms. Karen Hunady M.S.Director of Corp. Communications & Investor RelationsN/AN/AN/A
Ms. Alison O'Sullivan M.B.A.Sr. Director of HRN/AN/AN/A
Dr. Manal Morsy M.D., PH.D.Sr. VP & Head of Global Regulatory AffairsN/AN/AN/A
Dr. Robert MaysVP of Regenerative Medicine & Head of Neuroscience ProgramsN/AN/AN/A
Mr. Rakesh RamachandranHead of Information Technology & Communications and VPN/AN/AN/A
Ms. Maia Hansen M.B.A., M.S.Sr. VP and Head of Operations & Supply ChainN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

Corporate Governance

Athersys, Inc.’s ISS Governance QualityScore as of June 30, 2021 is 7. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.